The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Philip Charles Hoffman and Harvey M. Golomb.
Connection Strength

0.789
  1. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs. 2001; 19(4):329-33.
    View in: PubMed
    Score: 0.050
  2. A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin Lung Cancer. 2000 Nov; 2(2):128-32.
    View in: PubMed
    Score: 0.050
  3. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol. 1998 Oct; 9(10):1085-90.
    View in: PubMed
    Score: 0.043
  4. Ifosfamide-based three-drug combination regimens in non-small cell lung cancer. Semin Oncol. 1998 Feb; 25(1 Suppl 2):19-22.
    View in: PubMed
    Score: 0.041
  5. Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-67-S12-69.
    View in: PubMed
    Score: 0.040
  6. Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. Semin Oncol. 1997 Aug; 24(4 Suppl 14):S14-26-S14-29.
    View in: PubMed
    Score: 0.040
  7. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. Semin Oncol. 1996 Jun; 23(3 Suppl 6):11-5.
    View in: PubMed
    Score: 0.037
  8. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Semin Oncol. 1996 Apr; 23(2 Suppl 5):48-52.
    View in: PubMed
    Score: 0.036
  9. Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. Ann Oncol. 1996 Mar; 7(3):314-6.
    View in: PubMed
    Score: 0.036
  10. Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer. Semin Oncol. 1995 Aug; 22(4 Suppl 9):38-41.
    View in: PubMed
    Score: 0.035
  11. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
    View in: PubMed
    Score: 0.033
  12. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design. Semin Oncol. 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4.
    View in: PubMed
    Score: 0.033
  13. Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
    View in: PubMed
    Score: 0.031
  14. The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
    View in: PubMed
    Score: 0.028
  15. Role of systemic therapy in advanced non-small-cell lung cancer. Am J Med. 1990 Dec; 89(6):777-86.
    View in: PubMed
    Score: 0.025
  16. 5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
    View in: PubMed
    Score: 0.024
  17. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990 Aug; 8(8):1402-7.
    View in: PubMed
    Score: 0.024
  18. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
    View in: PubMed
    Score: 0.024
  19. Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer. Cancer. 1989 Oct 01; 64(7):1404-8.
    View in: PubMed
    Score: 0.023
  20. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
    View in: PubMed
    Score: 0.023
  21. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer. Cancer. 1989 Jan 15; 63(2):238-42.
    View in: PubMed
    Score: 0.022
  22. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol. 1998 Jun; 16(6):2157-63.
    View in: PubMed
    Score: 0.011
  23. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. Ann Oncol. 1998 Jun; 9(6):677-80.
    View in: PubMed
    Score: 0.011
  24. A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. Semin Oncol. 1998 Feb; 25(1 Suppl 2):8-14.
    View in: PubMed
    Score: 0.010
  25. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998 Jan; 16(1):159-64.
    View in: PubMed
    Score: 0.010
  26. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. J Clin Oncol. 1997 Mar; 15(3):884-92.
    View in: PubMed
    Score: 0.010
  27. Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago. Semin Oncol. 1996 Jun; 23(3 Suppl 7):15-8.
    View in: PubMed
    Score: 0.009
  28. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Semin Oncol. 1996 Apr; 23(2 Suppl 5):11-8.
    View in: PubMed
    Score: 0.009
  29. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):288-94.
    View in: PubMed
    Score: 0.009
  30. Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 5):30-7; discussion 41-4.
    View in: PubMed
    Score: 0.008
  31. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg. 1987 Nov; 44(5):462-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.